Tumor formation experiment showed that EphA2-WT dramatically increased in vivo tumorigenicity of NPC cells, whereas EphA2-YA slightly did it as compared to endogenous EphA2 knockdown (Fig. 1f, g), indicating that Y772A mutation almost abolished the effects of EphA2-WT on the in vivo tumorigenicity of NPC cells. Here, EPHA2 is linked to neoplasm.